Gotu Kola for Health & Longevity

Evidence Review created on 05/04/2026 using AI4L / Opus 4.7

Also known as: Centella asiatica, Indian Pennywort, Asiatic Pennywort, Brahmi (Ayurvedic — shared with Bacopa monnieri), Mandukaparni, Pegaga, Tigergrass, TECA, ECa 233

Motivation

Gotu Kola (Centella asiatica) is a small, creeping perennial plant of the carrot family that has been a staple of Ayurvedic and Traditional Chinese Medicine for at least two millennia, where it is classified as a rasayana — a rejuvenative tonic associated with longevity and skin healing. Standardized leaf extracts are registered as medicines in France and several Asian countries for chronic venous insufficiency and wound healing.

The scientific record is unusually heterogeneous. Pooled clinical data support benefit for venous and microcirculatory complaints and cosmetic skin endpoints, while parallel work on cognitive and neuroprotective effects has produced inconsistent results. A small but persistent series of liver-injury case reports has tempered the safety profile, and recent pharmacokinetic work clarifies which compounds reach systemic circulation.

This review examines standardized Centella asiatica leaf extract as a health and longevity intervention — its mechanisms, clinically supported benefits, known risks, and sourcing concerns — because the long history of traditional use and the mixed clinical record leave the risk-benefit picture genuinely unresolved for an optimization-oriented audience.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Centella asiatica - Grokipedia

The Grokipedia article gives a thorough overview of Centella asiatica — taxonomy in the Apiaceae family, native range across tropical Africa, Asia, Australia, and the western Pacific, ethnobotanical use as a rasayana in Ayurveda and as a wound and skin remedy in Traditional Chinese Medicine, and a survey of the principal triterpenoids (asiaticoside, madecassoside, asiatic acid) responsible for its pharmacological effects, alongside a balanced summary of clinical evidence and the rare hepatotoxicity signal.

Examine

Gotu Kola - Examine

The Examine Gotu Kola page summarizes evidence for cognitive enhancement, anxiety reduction, chronic venous insufficiency, diabetic microangiopathy (small-blood-vessel disease secondary to long-standing diabetes), and wound healing across roughly a dozen indications, recommending titrated extracts standardized to 30–60 mg total triterpene saponins per dose given two to three times daily, and noting a small number of hepatotoxicity case reports as the principal safety concern.

ConsumerLab

No dedicated ConsumerLab article exists for gotu kola as of 05/04/2026; ConsumerLab has not published a stand-alone Top Picks or product review for the intervention.

Systematic Reviews

This section presents the most relevant systematic reviews and meta-analyses of Centella asiatica, with the strongest evidence base concentrated in chronic venous insufficiency, wound healing, dermatologic outcomes, and cognitive/mood domains.

Phlebotonics for Venous Insufficiency - Martinez-Zapata et al., 2020

The 2020 Cochrane systematic review (CD003229.pub4) of 69 RCTs (7,690 participants) on phlebotonics — a class that includes Centella asiatica — for chronic venous insufficiency, finding moderate-certainty evidence that phlebotonics probably reduce leg edema (RR (Risk Ratio, the ratio of the probability of an event in two groups) 0.70, 95% CI (Confidence Interval, the range likely to contain the true effect) 0.63 to 0.78) and ankle circumference (MD (Mean Difference, the average between-group difference on a measured scale) −4.27 mm), with little or no effect on quality of life and a small but real increase in adverse events.
A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency - Chong & Aziz, 2013

A systematic review of 8 RCTs of Centella asiatica specifically (rather than the broader phlebotonic class) for chronic venous insufficiency, reporting significant improvements in microcirculatory parameters — transcutaneous CO2 and O2 partial pressures, ankle-swelling rate, and venoarteriolar response (a reflex constriction of small arteries when limb veins are pressurized, used as a microcirculatory function test) — alongside qualitative improvements in leg heaviness, pain, and edema, with the caveat that most included trials had unclear risk of bias.
Effects of Centella asiatica (L.) Urb. on Cognitive Function and Mood Related Outcomes: A Systematic Review and Meta-Analysis - Puttarak et al., 2017

A meta-analysis of 5 RCTs of Centella asiatica alone and 6 RCTs of Centella asiatica–containing combination products, finding no statistically significant effect on any cognitive domain compared with placebo, but a significant short-term improvement in alertness (SMD (Standardized Mean Difference, a unitless effect-size metric used in meta-analyses) 0.71) and reduction in anger (SMD −0.81) at 1 hour post-dose. The authors highlight extensive heterogeneity in dose, extract type, and product standardization as a major limitation.
Efficacy and Safety of Centella asiatica (L.) Urb. on Wrinkles: A Systematic Review of Published Data and Network Meta-Analysis - Kongkaew et al., 2020

A network meta-analysis of 5 double-blind RCTs (172 Asian female participants) on topical Centella asiatica preparations for facial wrinkles, concluding that C. asiatica gels and creams improved periocular and lip wrinkles and substantially raised skin hydration, with effects appearing greater than placebo and possibly less than tretinoin (a vitamin-A derivative used for skin aging) but with a far better short-term tolerability profile.
A Systematic Review of the Effect of Centella asiatica on Wound Healing - Arribas-López et al., 2022

A PRISMA-guided (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, the standard reporting framework) systematic review of 4 clinical trials of Centella asiatica for wound healing, finding consistent improvements in wound contraction, granulation, re-epithelialization time, and VAS (Visual Analogue Scale, a 0–10 self-report scale) pain scores, attributed mechanistically to stimulation of collagen I, FGF (Fibroblast Growth Factor, a family of proteins driving tissue regeneration), and VEGF (Vascular Endothelial Growth Factor, a protein that stimulates new blood-vessel formation), and to suppression of IL-1β (Interleukin-1 beta, a pro-inflammatory cytokine), IL-6 (Interleukin-6, a pro-inflammatory cytokine), TNFα (Tumor Necrosis Factor-alpha, a pro-inflammatory cytokine), COX-2 (Cyclooxygenase-2, an enzyme producing inflammatory prostaglandins), and LOX (Lipoxygenase, an enzyme producing inflammatory leukotrienes).

Mechanism of Action

Centella asiatica whole-leaf and standardized extracts contain four principal classes of bioactive constituents: (1) pentacyclic triterpene saponins — primarily asiaticoside and madecassoside (the glycosides) and their aglycone (sugar-removed) hydrolysis products asiatic acid and madecassic acid — collectively 1–8% of leaf dry weight; (2) phenolic acids and caffeoylquinic acids (CQAs); (3) flavonoids, mainly glycosides of quercetin and kaempferol; and (4) volatile sesquiterpenes. Pharmaceutical-grade preparations include TECA (Titrated Extract of Centella asiatica, standardized to 30% asiatic acid, 30% madecassic acid, and 40% asiaticoside) and ECa 233 (a standardized extract enriched in madecassoside and asiaticoside).

Key pharmacological properties: oral bioavailability of the parent glycosides asiaticoside and madecassoside is very low; instead, intestinal hydrolysis releases the aglycones asiatic acid and madecassic acid, which appear in plasma with peak concentrations at 2–4 hours and elimination half-lives of approximately 4–8 hours. Caffeoylquinic acids reach plasma primarily as colonic-microbiota-derived metabolites with delayed appearance. Hepatic metabolism involves Phase II glucuronidation and sulfation; minimal CYP3A4 (Cytochrome P450 3A4, an enzyme that metabolizes approximately half of clinically used drugs) inhibition has been observed at standard doses, but in vitro evidence of CYP1A2 (Cytochrome P450 1A2, an enzyme that metabolizes caffeine and several antipsychotics) modulation remains a theoretical interaction concern.

Key mechanisms include:

Collagen and extracellular matrix synthesis: Asiatic acid and asiaticoside upregulate type I and III collagen synthesis, fibronectin, and glycosaminoglycan deposition in fibroblasts, while inhibiting collagen-degrading MMPs (Matrix Metalloproteinases, a family of zinc-dependent enzymes that break down extracellular matrix). This dual effect underlies the wound-healing, scar-remodeling, varicose-vein, and skin-aging benefits
Vascular and endothelial effects: Centella asiatica extracts decrease capillary filtration and improve venous tone in chronic venous insufficiency by strengthening the venous wall connective-tissue matrix and reducing venous-hypertensive microangiopathy, with secondary improvement in microcirculatory flow
Antioxidant and Nrf2 activation: Triterpenes and CQAs activate the Nrf2 pathway, upregulating endogenous antioxidant enzymes including HO-1 (Heme Oxygenase-1, a stress-induced antioxidant enzyme), NQO1 (NAD(P)H Quinone Dehydrogenase 1, a Phase II detoxifying enzyme), and glutathione synthesis. Mitochondrial biogenesis markers including PGC-1α (Peroxisome proliferator-activated receptor Gamma Coactivator 1-alpha, the master regulator of mitochondrial biogenesis) are increased in preclinical models
Anti-inflammatory action: Asiaticoside and madecassoside inhibit NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells, a transcription factor central to inflammatory gene expression) activation, reducing TNF-α and IL-6 and lowering COX-2 expression
Neuroprotective and cognitive signaling: Aqueous extracts in animal models reduce amyloid-β (Amyloid-beta, the peptide that accumulates as plaques in Alzheimer’s disease) toxicity, restore mitochondrial complex activity, increase dendritic arborization in hippocampal neurons, and enhance BDNF (Brain-Derived Neurotrophic Factor, a protein that supports neuron survival and plasticity) expression. The 2022 Wright et al. Phase 1 trial demonstrated that oral extract elicits time-correlated NRF2-pathway gene expression changes in peripheral blood mononuclear cells in humans
Mild GABAergic and anxiolytic activity: Centella asiatica extracts modulate GABA-A (gamma-Aminobutyric Acid type A, the brain’s main inhibitory receptor) signaling and may inhibit cholesterol-dependent steroidogenesis, contributing to modest anxiolytic and stress-buffering effects observed in human GAD (Generalized Anxiety Disorder) trials

Competing mechanistic perspectives exist: skeptics note that absolute plasma concentrations of triterpene aglycones are far below those used in cell-culture and animal mechanistic studies, raising doubts about the in vivo relevance of much of the preclinical literature; advocates respond that the durable clinical effects in venous insufficiency and skin endpoints are reproducible in well-conducted trials and that low-bioavailability compounds may act locally on gut, vascular, or peripheral tissue without requiring high systemic exposure.

Historical Context & Evolution

Centella asiatica is a small, herbaceous perennial of the Apiaceae family, native to wetlands across South and Southeast Asia, southern Africa, parts of Australia, and the western Pacific. It has held a central place in Ayurvedic and Traditional Chinese Medicine pharmacopoeias for at least 2,000 years, classified in Ayurveda as mandukaparni (a medhya rasayana, or cognition-enhancing rejuvenative) and used in Traditional Chinese Medicine for “cooling” and detoxification, wound healing, and what would today be called venous insufficiency. The Chinese herbalist Li Ching-Yuen — historically credited (likely apocryphally) with extreme longevity in the early twentieth century — popularized Centella asiatica in the West as the “herb of longevity,” cementing the popular association.

Modern pharmacological investigation began in 1941 with Boiteau and colleagues at the Institut Pasteur (Madagascar branch), who isolated asiaticoside and demonstrated wound-healing activity. In 1949, the French pharmaceutical firm Laboratoires Servier developed Madecassol — the first standardized triterpene preparation — for the topical treatment of leprosy ulcers, burns, and post-surgical scars; it became a registered pharmaceutical in France in the early 1950s and remains in clinical use (note: Servier is a direct commercial sponsor of standardized Centella asiatica preparations, a financial interest carried through much of the subsequent venous-insufficiency trial literature). By the 1980s, the standardized titrated extract TECA (30:30:40 asiatic acid:madecassic acid:asiaticoside) was in widespread European use for chronic venous insufficiency, with multiple placebo-controlled randomized trials documenting reduction in lower-limb edema, leg heaviness, and capillary filtration rate.

The clinical trajectory has broadened in three directions over the past two decades. First, the venous insufficiency literature has been periodically synthesized, most rigorously in the 2013 Chong & Aziz systematic review and the 2020 Cochrane phlebotonics update, which together provide moderate-certainty evidence for symptomatic benefit; much of the underlying primary-trial work was led by the Belcaro and Cesarone groups in Chieti, Italy, whose studies have been repeatedly co-sponsored by manufacturers of standardized Centella asiatica preparations — a structural conflict of interest that runs through the venous and microcirculatory literature. Second, the dermatologic literature has expanded into facial wrinkles, hypertrophic scar prevention, and post-procedural wound care, culminating in the 2020 Kongkaew network meta-analysis. Third — and most contested — Centella asiatica has been investigated as a cognitive and neuroprotective agent: the OHSU group (Soumyanath, Quinn, and colleagues) has run a series of preclinical and Phase 1 human studies since the mid-2010s demonstrating Nrf2-pathway target engagement in older adults, while the 2017 Puttarak meta-analysis found no consistent cognitive-domain effect across heterogeneous trials. The mid-2000s saw several published case reports of clinically apparent acute hepatocellular injury attributed to Centella asiatica preparations — most prominently a 2008 Argentinian case series of three women using gotu kola for weight loss, and a 2011 Swiss case after acne use — which prompted the inclusion of Centella asiatica in the U.S. NIH LiverTox database and formal European pharmacovigilance attention. The original venous-insufficiency RCT data, the negative cognitive trials, and the hepatotoxicity case series are all available for inspection.

Expected Benefits

Medium 🟩 🟩

Reduction in Chronic Venous Insufficiency Symptoms

Standardized Centella asiatica extracts (typically TECA 60–180 mg/day) reduce the lower-limb signs and symptoms of chronic venous insufficiency — including leg heaviness, ankle and calf edema, perimalleolar swelling, and microangiopathic complications — through documented effects on venous wall connective-tissue integrity, capillary filtration, and microcirculatory flow. The 2013 Chong & Aziz systematic review of 8 RCTs and the 2020 Cochrane phlebotonics review (which subsumed Centella asiatica trials within the broader phlebotonic class) both support modest but reproducible benefit, with moderate-certainty evidence for edema reduction. Symptomatic improvement is most consistent at 4–8 weeks of continuous dosing.

Magnitude: Mean ankle-circumference reduction of ~4 mm versus placebo across phlebotonic-class RCTs; risk ratio for edema reduction approximately 0.70 (95% CI 0.63 to 0.78); relief of leg heaviness reported in ~60–70% of treated patients versus ~30% on placebo in Centella asiatica–specific trials.

Improved Wound and Burn Healing

Topical and oral Centella asiatica preparations accelerate wound contraction, granulation, and re-epithelialization in surgical wounds, burns, episiotomies (surgical incisions of the perineum during childbirth), and pressure ulcers, attributed mechanistically to stimulation of collagen I, FGF, and VEGF and to suppression of inflammatory cytokines and matrix-degrading enzymes. The 2022 Arribas-López systematic review of 4 clinical trials and the long-standing pharmaceutical use of Madecassol since the 1950s underpin this benefit. Effects are most consistent for clean acute wounds and post-surgical scars; chronic-wound and diabetic-ulcer evidence remains preliminary.

Magnitude: Wound contraction approximately 1.2–1.5× faster than control across included trials; re-epithelialization time reduced by 1–4 days depending on wound type; pain VAS reduced by 1–3 points on 0–10 scales.

Low 🟩

Improvement in Facial Skin Aging and Wrinkles

Topical Centella asiatica preparations (gels, creams, and proprietary cosmeceutical formulations) reduce periocular and perioral wrinkling and increase stratum-corneum hydration, attributed to triterpene-driven dermal collagen synthesis and antioxidant protection. The 2020 Kongkaew network meta-analysis of 5 double-blind RCTs (172 Asian female participants) found Centella asiatica superior to placebo and possibly less effective than tretinoin, but with markedly fewer adverse events. Evidence is limited to short-duration (8–12 week) trials in younger women; longer-term outcomes and effects in non-Asian populations are not well characterized.

Magnitude: Visual wrinkle-score reduction of 10–25% over 12 weeks; skin hydration increased by 15–30% versus baseline. No quantified comparison to tretinoin.

Reduction in Anxiety and Stress Symptoms

Oral Centella asiatica extracts (typically 500 mg twice daily of a 70% hydro-ethanolic extract) appear to reduce anxiety and stress symptoms in patients with generalized anxiety disorder, with the principal evidence being an open-label clinical study by Jana et al. (2010) in 33 GAD patients showing approximately 26% reduction in Hamilton anxiety scores at 60 days. The 2017 Puttarak meta-analysis additionally documented short-term mood effects (increased alertness, reduced anger 1 hour post-dose) across several trials. Preclinical mechanisms involve GABA-A modulation and Nrf2 activation. Evidence is limited by small open-label trials and considerable extract heterogeneity.

Magnitude: Hamilton Anxiety Rating Scale reductions of approximately 20–26% over 60 days in the Jana 2010 GAD trial; SMD 0.71 for short-term alertness in pooled meta-analysis.

Reduction in Diabetic Microangiopathy Symptoms

Standardized Centella asiatica extracts reduce capillary filtration rate, ankle edema, and microcirculatory dysfunction in patients with diabetic microangiopathy and venous-hypertensive microangiopathy, as documented in placebo-controlled randomized trials by the Belcaro and Cesarone groups in Italy during the late 1990s and early 2000s (these studies were repeatedly co-sponsored by manufacturers of standardized Centella asiatica preparations — a commercial conflict of interest that affects much of this evidence). The mechanism overlaps substantially with the venous-insufficiency benefit (capillary-wall stabilization, reduced vascular permeability) but extends specifically to the microvascular dysfunction characteristic of diabetes.

Magnitude: Capillary filtration rate reduced by approximately 30–40% versus placebo over 4–8 weeks of treatment in the dose-ranging Italian trials.

Speculative 🟨

Cognitive Enhancement in Healthy Aging ⚠️ Conflicted

The traditional Ayurvedic and modern preclinical literature consistently characterize Centella asiatica as a medhya rasayana — a cognitive-enhancing rejuvenative — but human evidence in healthy adults is inconsistent. The 2017 Puttarak meta-analysis found no significant effect across cognitive domains, although small individual trials (e.g., Wattanathorn 2008 in healthy elderly volunteers) have reported working-memory and event-related-potential improvements at 750 mg/day. The 2022 Wright Phase 1 trial demonstrated that target engagement is measurable in humans, but efficacy trials in cognitively healthy adults remain absent. The basis for inclusion is mechanistic (Nrf2 activation, BDNF, mitochondrial biogenesis) and traditional, not clinical-trial.

Atherosclerotic Plaque Stabilization

Three-year observational and randomized work by the Belcaro group in Italy, often combined with French maritime pine bark (Pycnogenol), has reported reduced carotid-plaque progression and improved plaque-cap stability with Centella asiatica 450–675 mg/day. The proposed mechanism — fibroblast-mediated collagen-cap reinforcement — is biologically plausible but rests on small studies from a single research group with potential commercial conflicts (the manufacturer of standardized preparations co-sponsored the work). The basis for inclusion is mechanistic and observational only; large independent trials are absent.

Healthy-Lifespan Extension via Nrf2 and Mitochondrial Pathways

Animal studies in Drosophila, Caenorhabditis elegans, and rodent models report lifespan and healthspan extension with Centella asiatica extracts, attributed to Nrf2 pathway activation, mitochondrial biogenesis, and senescence-pathway modulation. Translation to human longevity outcomes is unestablished; no RCT in humans has yet examined long-term mortality, frailty, or biological-age endpoints. The basis for inclusion is preclinical and traditional only.

Benefit-Modifying Factors

Age: Age-related venous-wall weakening and reduced microcirculatory reserve mean older adults are more likely to experience symptomatic relief from Centella asiatica in venous-insufficiency contexts. The OHSU cognitive work has focused on cognitively impaired older adults specifically because the Nrf2-pathway dysregulation that Centella asiatica targets becomes more pronounced with age. Older adults also clear triterpene aglycones more slowly, with potential for higher steady-state plasma concentrations
Sex: The cosmetic and dermatologic literature is overwhelmingly conducted in women, partly because of trial-recruitment patterns and partly because of higher reported tolerability and uptake. The hepatotoxicity case series, conversely, are also predominantly in women — likely reflecting use patterns rather than sex-specific susceptibility, though estrogen-modulated hepatic Phase II metabolism cannot be excluded as a contributing factor
Baseline biomarker levels: Patients with baseline elevations in capillary filtration rate, ankle edema, or transcutaneous PCO2/PO2 (partial pressure of carbon dioxide and oxygen measured through the skin, used to assess microcirculatory exchange) abnormalities show the largest microcirculatory improvements with Centella asiatica in dose-ranging Italian RCTs. In cognitive trials, baseline mild cognitive impairment with measurable Nrf2-pathway dysregulation may identify responders, though this hypothesis is preliminary
Pre-existing health conditions: Th2-dominant autoimmune conditions (e.g., some Hashimoto’s thyroiditis cases per Kresser’s framing) may experience worsening of immune skewing with Centella asiatica use. Pre-existing liver disease — including subclinical NAFLD (Non-Alcoholic Fatty Liver Disease) — likely raises the risk of clinically apparent hepatotoxicity, and patients with pre-existing chronic venous insufficiency comorbid with arterial disease may benefit from greater microcirculatory effect
Genetic polymorphisms: Variants in NFE2L2 (the gene encoding Nrf2, the master transcription factor activating endogenous antioxidant defenses) and KEAP1 (the cytoplasmic sensor protein that normally holds Nrf2 inactive and releases it under oxidative stress) plausibly modify response to the Nrf2-mediated antioxidant effect, though pharmacogenetic evidence is preclinical only. Variants in UGT (UDP-glucuronosyltransferase, the Phase II conjugation enzyme family that attaches glucuronic acid to lipophilic compounds for excretion) — the principal pathway for triterpene aglycone clearance — may influence plasma concentrations and both effectiveness and liver-injury risk, although this remains unconfirmed in clinical practice

Potential Risks & Side Effects

Medium 🟥 🟥

Idiosyncratic Hepatotoxicity

A small but persistent series of published case reports — most prominently the 2008 Argentinian three-patient case series and a 2011 Swiss case after acne use — has documented clinically apparent acute hepatocellular injury with jaundice attributed to oral Centella asiatica. Time to onset ranges from 3 to 8 weeks; the pattern is hepatocellular and resolves within 1–2 months of discontinuation. The mechanism is unknown and is suspected to be idiosyncratic, possibly immune-mediated, with the role of contamination or non-Centella hepatotoxins in commercial products not excluded. Centella asiatica is included in the U.S. NIH LiverTox database with a designation indicating rare clinically apparent injury. Severity ranges from mild aminotransferase elevation to severe cholestatic jaundice (yellowing of the skin and eyes from impaired bile flow); no fatalities have been confirmed.

Magnitude: Fewer than 10 well-documented case reports worldwide as of 2026 against an estimated multi-million annual users; absolute risk plausibly <1 per 100,000 users but precise estimates are unavailable.

Low 🟥

Gastrointestinal Discomfort

Centella asiatica — particularly at higher oral doses or when taken on an empty stomach — produces mild gastrointestinal upset including nausea, abdominal discomfort, and altered stool consistency in a minority of users. Mechanism is uncertain but likely involves direct mucosal effect of triterpene saponins, which have surfactant-like properties. The 2020 Cochrane phlebotonics review reported that gastrointestinal disorders were the most frequently reported adverse events across phlebotonic-class trials, with a small but real increase versus placebo (RR 1.14, 95% CI 1.02 to 1.27).

Magnitude: Approximately 5–10% incidence of gastrointestinal complaints versus 3–7% on placebo in pooled phlebotonics trials; usually mild and resolving with dose reduction or food co-administration.

Headache and Drowsiness

A minority of users report headache, drowsiness, or mild sedation, particularly at higher oral doses or with long-term use. Mechanism likely involves the modest GABAergic activity of Centella asiatica triterpenes, which underlies the documented anxiolytic effects but can manifest as unwanted sedation in some users. Most reports are short-lived and resolve with dose reduction.

Magnitude: Not quantified in available studies.

Allergic Contact Dermatitis (Topical)

Topical Centella asiatica preparations occasionally produce allergic contact dermatitis, with the triterpene asiaticoside identified as the principal sensitizing agent in patch-testing series. The reaction is typically erythematous, pruritic, and resolves with discontinuation, but may persist or recur on rechallenge. Risk is higher in patients with pre-existing chronic skin disease (stasis dermatitis (an inflammatory skin condition arising from chronic venous insufficiency), varicose ulcers) where prolonged topical use is common.

Magnitude: Estimated 1–5% of regular topical users in dermatology case series; absolute incidence in unselected population is much lower.

Speculative 🟨

Photosensitivity

A theoretical concern based on isolated case reports and the photosensitizing potential of related furanocoumarin-containing Apiaceae family members; no controlled human data demonstrate clinically meaningful photosensitivity with standardized Centella asiatica extracts. Basis is mechanistic and from isolated reports only.

Pregnancy and Lactation Risk

Animal studies report uterine-stimulant activity at high doses and theoretical concerns about teratogenicity from triterpene saponins, but no controlled human data exist. Most regulatory bodies and pharmacovigilance authorities classify Centella asiatica as contraindicated in pregnancy by precautionary principle, and the U.S. NIH LiverTox database notes lack of safety data in lactation. Basis is mechanistic and precautionary.

Mild Hyperglycemia ⚠️ Conflicted

Isolated reports and a few small animal studies suggest modest blood-glucose elevation with Centella asiatica, while other reports describe the opposite (hypoglycemic effect). The signal is inconsistent and may reflect product or chemotype differences. Basis is mechanistic and from isolated reports only.

Risk-Modifying Factors

Age: Older adults clear triterpene aglycones more slowly through hepatic Phase II conjugation, with theoretical potential for elevated steady-state plasma concentrations and greater hepatotoxicity risk. Older adults also have reduced hepatic regenerative capacity if injury occurs
Sex: Documented hepatotoxicity case reports are predominantly in women, although this likely reflects use patterns (weight-loss and cosmetic indications) rather than sex-specific susceptibility. Estrogen-modulated UGT and CYP1A2 activity could theoretically influence aglycone clearance
Baseline biomarker levels: Baseline elevation of ALT (Alanine Aminotransferase, a liver enzyme released into blood when hepatocytes are damaged) or AST (Aspartate Aminotransferase, another liver enzyme used to assess hepatocyte injury) signals existing hepatocellular stress and likely raises the risk of clinically apparent injury with oral Centella asiatica. Elevated baseline GGT (Gamma-Glutamyl Transferase, a liver enzyme sensitive to cholestatic and oxidative liver stress) similarly raises concern
Pre-existing health conditions: Pre-existing liver disease — including subclinical NAFLD, hepatitis B or C, alcohol-related liver disease, or polypharmacy with other hepatotoxic agents — raises the risk of clinically apparent hepatotoxicity. Th2-dominant autoimmune conditions may experience worsening of immune skewing. Pre-existing seizure disorder is a theoretical concern given GABAergic modulation, though no clinical reports of seizure precipitation exist
Genetic polymorphisms: Variants in UGT and SULT (Sulfotransferase, Phase II enzymes that conjugate small molecules with sulfate) plausibly modify aglycone clearance and hepatotoxicity risk; HLA (Human Leukocyte Antigen, the gene complex encoding immune-recognition molecules) class II variants are associated with susceptibility to idiosyncratic drug-induced liver injury for many compounds and could theoretically apply to Centella asiatica, although no specific allele has been identified

Key Interactions & Contraindications

Hepatotoxic medications and supplements (caution): Co-administration with other potentially hepatotoxic agents — including acetaminophen at chronic high doses, statins, antifungals (ketoconazole, terbinafine), kava, comfrey, chaparral, or high-dose niacin — may compound the rare but documented idiosyncratic hepatotoxicity risk. Mitigation: avoid stacking, monitor liver enzymes every 4–8 weeks during combined use
Sedative-hypnotic drugs (caution): Benzodiazepines (diazepam, lorazepam, alprazolam), Z-drugs (zolpidem, eszopiclone), barbiturates, and sedating antihistamines may have additive central-depressant effects with Centella asiatica given its modest GABAergic activity. Clinical consequence: increased drowsiness or impaired coordination. Mitigation: dose reduction or temporal separation
Anticoagulants and antiplatelet drugs (caution): Warfarin, direct oral anticoagulants (apixaban, rivaroxaban, dabigatran), aspirin, clopidogrel, and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs, a class including ibuprofen and naproxen) — Centella asiatica may modestly enhance bleeding risk through preliminary in vitro evidence of platelet-aggregation inhibition. Clinical consequence: theoretical increased bleeding. Mitigation: discontinue 1–2 weeks before elective surgery; monitor INR (International Normalized Ratio, the standardized measure of warfarin effect) more frequently if combined with warfarin
Antidiabetic medications (monitor): Sulfonylureas (glipizide, glyburide), insulin, GLP-1 (Glucagon-Like Peptide-1, an incretin hormone targeted by drugs like semaglutide) receptor agonists, and metformin — inconsistent reports of hyperglycemic and hypoglycemic effects with Centella asiatica warrant blood-glucose monitoring during initiation. Clinical consequence: unpredictable glycemic excursions. Mitigation: home glucose monitoring; adjust antidiabetic dose if needed
CYP1A2 substrates with narrow therapeutic index (theoretical caution): Theophylline, tizanidine, and certain antipsychotics (clozapine, olanzapine) — in vitro CYP1A2 modulation by Centella asiatica extracts raises a theoretical interaction concern. Clinical consequence: altered drug levels. Mitigation: monitor plasma drug levels where available
Other supplements with additive hepatotoxic or sedative effect: Kava, valerian, passionflower, and ashwagandha (sedative-additive); green tea extract at high doses, comfrey, chaparral, and pyrrolizidine-alkaloid–containing herbs (hepatotoxic-additive). Mitigation: avoid stacking
Populations who should avoid Centella asiatica (absolute contraindication):
- Pregnancy (uterine-stimulant activity in animal models; no controlled human data)
- Lactation (no controlled human data)
- Active liver disease — including hepatitis B or C, autoimmune hepatitis, decompensated cirrhosis (Child-Pugh Class B or C)
- Children under 18 (insufficient data)
- Scheduled elective surgery within 2 weeks (theoretical bleeding risk)
Populations who should avoid Centella asiatica (relative contraindication):
- Th2-dominant autoimmune disease (some Hashimoto’s, atopic disease, eosinophilic conditions)
- Pre-existing elevated ALT or AST >1.5× upper limit of normal
- Concurrent use of multiple hepatotoxic medications
- Seizure disorder (theoretical GABAergic interaction)

Risk Mitigation Strategies

Baseline and periodic liver enzyme monitoring: Obtain baseline ALT, AST, alkaline phosphatase, total and direct bilirubin, and GGT before initiating oral Centella asiatica, repeating at 4–8 weeks and then every 3–6 months during continued use. Mitigates: idiosyncratic hepatotoxicity by enabling early detection before clinically apparent injury
Use only standardized, third-party-tested products: Select products standardized to defined triterpene saponin content (e.g., 30:30:40 TECA standardization, or labeled asiaticoside/madecassoside content) and certified by USP (United States Pharmacopeia, a non-profit drug-quality standards body), NSF International, or equivalent third-party programs. Mitigates: hepatotoxicity from contamination, mislabeling, or non-Centella hepatotoxins, and dose variability that may compromise efficacy
Start at low dose and titrate: Initiate at 60 mg/day of standardized extract and titrate to 120–180 mg/day over 2–4 weeks. Mitigates: gastrointestinal discomfort, headache, and drowsiness, while allowing early identification of idiosyncratic adverse reactions
Take with food: Co-administer with meals to reduce gastrointestinal saponin-driven mucosal irritation. Mitigates: gastrointestinal discomfort and nausea
Limit continuous oral use to defined courses with breaks: Use in 4–6 week courses for venous-insufficiency or wound-healing indications, with planned 2–4 week off-periods, rather than uninterrupted long-term dosing. Mitigates: cumulative hepatotoxicity risk and tolerance development
Discontinue 1–2 weeks before elective surgery: Stop oral Centella asiatica at least 7–14 days before any planned surgical procedure. Mitigates: theoretical antiplatelet and bleeding-risk interaction with surgery and concomitant anticoagulants
Patch-test before extensive topical use: Apply a small amount of any new topical Centella asiatica preparation to a 2 × 2 cm forearm area for 48 hours before broader application. Mitigates: allergic contact dermatitis, particularly in patients with stasis dermatitis or other chronic skin conditions
Avoid stacking with hepatotoxic agents: Do not combine Centella asiatica with chronic high-dose acetaminophen, kava, comfrey, chaparral, or high-dose green tea extract; review concurrent statin and antifungal therapy with prescriber. Mitigates: additive hepatotoxicity

Therapeutic Protocol

The standard protocol used by leading practitioners is centered on standardized triterpene-saponin content rather than gross extract weight. Two distinct protocol traditions exist: the European phlebotonic protocol — popularized by Laboratoires Servier (Madecassol/TECA) and the Belcaro group’s Pap II trials — for venous insufficiency and microangiopathy; and the Ayurvedic/integrative cognitive protocol — described in the work of Soumyanath and colleagues at OHSU and in Ayurvedic compendia — for cognitive support. A separate dermatologic-topical protocol applies for skin-aging and wound-healing indications. Neither approach is positioned as the default; product selection should match the targeted endpoint.

Standard venous insufficiency / microangiopathy protocol (European phlebotonic tradition): TECA 60 mg three times daily (180 mg/day total) of triterpene-standardized extract, taken with meals for 4–8 weeks, with optional continuation in 4-week-on / 2-week-off cycles. Originating practice: Laboratoires Servier’s Madecassol formulary use in France since the 1950s; refined by Belcaro and Cesarone groups in Italy in the 1990s–2000s
Standard cognitive support / medhya rasayana protocol (integrative tradition): Standardized aqueous or hydro-ethanolic extract delivering 250–750 mg total extract daily, taken once or twice daily with food for ≥8 weeks before assessing effect. The OHSU Phase 1 work has used 2 g and 4 g of a standardized water extract single-dose; chronic dosing protocols are still being refined
Standard anxiolytic protocol (Jana 2010 GAD model): 70% hydro-ethanolic extract 500 mg twice daily (1,000 mg/day total) with meals for 60 days, with effect assessed at 30 and 60 days
Topical dermatologic protocol: Cream or gel containing 0.1–1% asiaticoside or 1–5% standardized Centella asiatica extract applied once or twice daily to target area for 8–12 weeks for wrinkle, scar, or wound endpoints
Best time of day: Oral dosing is conventionally split across the day with meals to reduce gastrointestinal discomfort. The mild GABAergic activity may favor evening dosing in users prone to daytime drowsiness; conversely, the alertness signal from the Puttarak meta-analysis (1 hour post-dose) favors morning dosing in cognitive contexts
Half-life and dosing frequency: The active triterpene aglycones asiatic acid and madecassic acid have plasma half-lives of approximately 4–8 hours, supporting two-to-three-times-daily dosing for sustained exposure rather than once-daily dosing
Single vs. split dose: Total daily dose is typically split into 2–3 administrations to maintain steady plasma concentrations and to reduce per-dose gastrointestinal load
Genetic polymorphisms influencing protocol: Variants in UGT (UDP-Glucuronosyltransferase, the Phase II conjugation enzyme family responsible for triterpene aglycone clearance) and SULT may influence plasma concentrations and tolerability, although pharmacogenetic dose-adjustment guidance is not established. NFE2L2 (the gene encoding Nrf2) variants may modify response to the Nrf2-mediated mechanism; this remains preclinical-only
Sex-based differences: No formal sex-stratified dosing guidance exists. The cosmetic literature is overwhelmingly female; the venous-insufficiency literature is mixed; the hepatotoxicity case series skew female (likely use-pattern effect)
Age-related considerations: Older adults (≥65 years) generally require the same nominal dose but may tolerate it less well due to slower hepatic clearance and higher prevalence of polypharmacy. Conservative initial dosing (60 mg/day) and earlier follow-up (2–4 weeks) are appropriate
Baseline biomarker considerations: Patients with elevated baseline capillary filtration rate, ankle edema, or transcutaneous PCO2/PO2 abnormalities are most likely to show measurable benefit in venous-insufficiency contexts. Baseline ALT/AST elevation should prompt reconsideration or closer monitoring
Pre-existing health conditions: Patients with concurrent venous and arterial disease, NAFLD, diabetes, or autoimmune disease require individualized risk-benefit assessment and closer monitoring

Discontinuation & Cycling

Course-based rather than lifelong use: Centella asiatica is conventionally used in defined courses (4–12 weeks) for specific indications (venous symptoms, wound healing, anxiety, skin-aging) rather than as a continuous lifelong supplement. The traditional Ayurvedic rasayana framework, in contrast, supports longer-term use, but modern pharmacovigilance considerations favor course-based dosing with planned breaks
Cycling protocol: A typical cycling schedule is 4–6 weeks on followed by 2–4 weeks off, repeated as needed for the targeted indication. Cycling reduces cumulative hepatotoxicity exposure and allows periodic biomarker re-assessment
No documented withdrawal effects: No clinically significant withdrawal syndrome has been described upon discontinuation of Centella asiatica. Mild rebound of underlying venous symptoms or anxiety may occur as the active extract clears, but this reflects recurrence of the underlying condition rather than a drug-withdrawal phenomenon
Tapering not required: Given the absence of a withdrawal syndrome and the relatively short half-life of active triterpene aglycones, abrupt discontinuation is acceptable. Patients on long-term high doses may consider a 1–2 week taper purely as a safety check
Discontinue if hepatotoxicity signal emerges: Any unexplained ALT or AST elevation >3× upper limit of normal, jaundice, dark urine, fatigue, or right-upper-quadrant pain warrants immediate discontinuation and hepatology evaluation. Re-challenge after recovery is generally not recommended given the idiosyncratic nature of the injury

Sourcing and Quality

Standardization to triterpene saponin content: Select products explicitly standardized to defined asiaticoside, madecassoside, asiatic acid, and madecassic acid content — ideally the TECA 30:30:40 ratio (asiatic acid : madecassic acid : asiaticoside) or a labeled total triterpene saponin percentage (typically 1–8% in raw leaf, 30–60% in concentrated extracts). Avoid raw-powder products without documented standardization
Third-party testing certification: Prefer products certified by USP, NSF International, ConsumerLab, or Informed-Choice, which verify content, contaminant limits (heavy metals, pesticides, microbial), and GMP (Good Manufacturing Practice, the FDA-mandated quality framework for dietary supplements) manufacturing. ConsumerLab has not published a stand-alone Top Picks review for gotu kola as of 2026
Geographic origin and chemotype variation: Centella asiatica triterpene profile varies substantially by geographic origin and ecotype — Indian and Sri Lankan plants typically have higher asiaticoside content, Madagascar plants higher asiatic acid, and East Asian plants intermediate profiles. Reputable products specify origin and chemotype where relevant
Reputable brand and pharmaceutical-preparation options: Pharmaceutical-grade options include Madecassol (Laboratoires Servier, France/global; topical and oral forms) and TECA-based generic preparations registered in France, Italy, and Spain. Supplement-grade brands with credible standardization and third-party verification include Pure Encapsulations, Thorne, Life Extension, and Jarrow Formulas. Compounding pharmacies can also prepare topical asiaticoside preparations to physician specification
Avoid bladderwrack and unrelated-herb co-formulation pitfalls: A 2012 ConsumerLab-noted FDA recall by Eclectic Institute involved supplements combining gotu kola with bladderwrack (Fucus vesiculosus), where iodine contamination was the primary concern. Single-ingredient or well-characterized small-formulation products are generally preferable for traceability and adverse-event attribution

Practical Considerations

Time to effect: Symptomatic relief in venous insufficiency typically begins at 2–4 weeks and reaches plateau at 6–8 weeks. Wound-healing acceleration is observable within 1–3 weeks. Cognitive and anxiolytic effects, where present, generally require 4–8 weeks of continuous dosing. Topical dermatologic effects (wrinkle reduction) require 8–12 weeks
Common pitfalls: (1) Using non-standardized raw-leaf powder products, which provide unpredictable triterpene exposure; (2) confusing Centella asiatica with Bacopa monnieri — both are referred to as “Brahmi” in some Ayurvedic traditions, but they are botanically and pharmacologically distinct; (3) continuous long-term oral use without periodic liver-enzyme monitoring; (4) co-administration with multiple hepatotoxic agents; (5) expecting cognitive effects in healthy adults despite the negative meta-analytic evidence; (6) using during pregnancy or lactation despite contraindication
Regulatory status: In the United States, Centella asiatica is classified as a dietary supplement under DSHEA (Dietary Supplement Health and Education Act, the 1994 U.S. law governing supplement regulation) and is not FDA-approved for any indication. In France, Italy, Spain, and several Asian countries, standardized triterpene preparations (TECA, Madecassol, ECa 233) are registered as prescription or over-the-counter pharmaceuticals for venous insufficiency, microangiopathy, and wound healing. The European Medicines Agency Herbal Medicinal Products Committee has published a Centella asiatica monograph supporting traditional use for minor wounds and venous symptoms
Cost and accessibility: Standardized supplement-grade Centella asiatica (60–180 mg/day of standardized extract) typically costs $0.30–$0.80 per day at U.S. retail; pharmaceutical-grade preparations in Europe cost slightly more but are often partially reimbursed. Topical Madecassol-class preparations are widely available in Europe and Asia and increasingly available through specialty channels in the U.S.

Interaction with Foundational Habits

Sleep: Centella asiatica’s mild GABAergic activity may modestly improve sleep onset and reduce mid-night anxiety in users with stress-related sleep disturbance, although controlled sleep-architecture data are absent. Direction: indirect-positive in anxious users; potentiating with other GABAergic agents (alcohol, benzodiazepines). Practical: evening dosing for users prone to daytime drowsiness; morning dosing for users seeking alertness benefit
Nutrition: Centella asiatica triterpenes are lipophilic and oral absorption is improved when taken with meals containing some dietary fat. Direction: direct-positive for absorption with food. Practical: take with breakfast and dinner; avoid empty-stomach administration both for absorption and for gastrointestinal tolerability. No documented nutrient depletions
Exercise: Preclinical work suggests Centella asiatica enhances mitochondrial biogenesis (PGC-1α, NRF1/NRF2 pathway) — the same pathway upregulated by aerobic exercise — raising the theoretical possibility of additive or even synergistic effects. Direction: theoretically potentiating; mechanism unverified in human exercise studies. Practical: timing relative to exercise has not been studied; co-administration appears safe. The mild antiplatelet effect is not expected to influence exercise tolerance but warrants caution before contact-sport participation if bleeding risk is otherwise elevated
Stress management: Centella asiatica’s anxiolytic and stress-buffering effects (per the Jana 2010 GAD trial and the Puttarak meta-analysis short-term mood data) align well with formal stress-management practices including meditation, breathwork, and yoga. Direction: direct-positive on stress-related symptoms; potentiating with other adaptogens (ashwagandha, Bacopa monnieri, Rhodiola rosea). Practical: traditional Ayurvedic use combines Centella asiatica with meditation practice; modern users may pair daily dosing with structured stress-reduction programs for cumulative benefit. Cortisol-axis effects in humans are not well characterized

Monitoring Protocol & Defining Success

Baseline testing is undertaken before initiating oral Centella asiatica to establish a hepatic-safety baseline and to characterize the targeted endpoint (venous, cognitive, dermatologic). Ongoing monitoring frequency depends on the indication and dose: at minimum, liver enzymes at 4–8 weeks after initiation, then every 3–6 months during continued use; condition-specific endpoints (e.g., ankle circumference, anxiety scale, wrinkle assessment) are reassessed at clinically appropriate intervals.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT	<20 U/L (men), <17 U/L (women)	Detects liver-cell injury — the principal serious adverse event with oral Centella asiatica	Alanine Aminotransferase, a liver enzyme released into blood when liver cells are damaged. Conventional reference range typically up to 40–55 U/L; functional medicine practitioners use tighter cutoffs. Fasting recommended; check at baseline, 4–8 weeks, then every 3–6 months
AST	<20 U/L	Cross-checks ALT; AST elevations also reflect muscle injury from exercise	Aspartate Aminotransferase, another liver enzyme used to assess liver-cell injury. Conventional reference range typically up to 40 U/L; pair with ALT. Avoid heavy exercise 24–48 hours before draw
GGT	<16 U/L (women), <25 U/L (men)	Sensitive marker of cholestatic and oxidative liver stress; abnormal before ALT/AST in some idiosyncratic injuries	Gamma-Glutamyl Transferase, a liver enzyme sensitive to bile-flow and oxidative liver stress. Conventional reference range typically up to 50–65 U/L; tighter functional cutoff. Fasting recommended
Total and Direct Bilirubin	Total <1.0 mg/dL; Direct <0.3 mg/dL	Detects clinically apparent jaundice — the threshold for serious injury	Pair with ALT/AST; rising direct bilirubin with elevated ALT defines Hy’s law (a regulatory benchmark for serious drug-induced liver injury risk) and is a serious-injury signal
Alkaline Phosphatase	40–100 U/L	Cholestatic-injury marker; rises before clinical jaundice in some hepatotoxicity patterns	Bone source must be considered in older adults; conventional range similar to functional
Ankle Circumference (cm, 2 cm above medial malleolus)	Symmetric, no >0.5 cm increase from morning to evening	Quantifies edema in venous-insufficiency indication	Conventional vascular practice uses standardized landmarks; measure morning and evening
Hamilton Anxiety Rating Scale (HAM-A)	<8 (minimal/no anxiety)	Quantifies anxiolytic response in GAD-indication use	Validated structured 14-item clinician-administered scale; baseline and at 4–8 weeks
Capillary Filtration Rate (where available)	<5 mL/100 mL/min/100 mmHg	Microcirculatory function in venous and diabetic microangiopathy	Specialized vascular-laboratory test; not routinely available in primary care

Qualitative markers to track:

Leg heaviness, evening swelling, calf cramping (venous indication)
Wound-healing rate and quality, scar appearance (wound and dermatology indication)
Subjective anxiety, sleep onset, morning alertness (anxiolytic indication)
Skin texture, hydration, fine-line appearance (cosmetic indication)
Any new fatigue, jaundice, dark urine, right-upper-quadrant discomfort (hepatotoxicity surveillance — discontinue immediately and seek evaluation)
Cognitive subjective measures (focus, working memory) — interpret cautiously given negative meta-analytic evidence

Emerging Research

OHSU Centella asiatica trials in cognitive impairment: The Oregon Health & Science University group (Soumyanath, Quinn, and colleagues) has run a Phase 1 pharmacokinetic and target-engagement trial — published as Wright et al., 2022 — demonstrating measurable NRF2-pathway gene expression changes in mildly demented older adults after a single oral dose of standardized aqueous extract. A follow-on safety and target-engagement study in mild cognitive impairment and Alzheimer’s disease is currently recruiting at NCT05591027, with 48 planned participants receiving 6 weeks of extract or placebo and the primary endpoint biological signatures of target engagement
Centella asiatica and vascular endothelial function in older adults: A trial sponsored by the National University of Natural Medicine — NCT06472791 — is examining the effects of oral Centella asiatica dietary supplement on vascular endothelial function in 30 older adults, addressing the gap in human translation of the preclinical Nrf2 and endothelial-function mechanism work and extending the historical phlebotonic literature into the broader cardiovascular-aging endpoint
Centella asiatica facial mask in dermatologic conditions: A multicenter randomized half-face controlled trial — NCT06763367 — is examining a Centella asiatica–infused facial mask for rosacea, acne, and melasma in 30 participants, extending the wrinkle-focused 2020 Kongkaew network meta-analysis into the broader inflammatory-skin-disease space
Asiaticoside as endodontic intracanal medication: A Phase 2/3 trial at Mansoura University — NCT06566508 — is investigating asiaticoside (the principal Centella asiatica triterpene glycoside) as an intracanal medicament for apical periodontitis (root-canal–associated inflammation), broadening the antimicrobial and anti-inflammatory mechanism evidence into a novel clinical context
Brahmi-Gotu Kola oil foot massage in perimenopause: A small randomized controlled trial — NCT07274371 — is comparing nightly Brahmi-Gotu Kola oil foot massage with sesame-oil control for sleep and mood in perimenopausal women aged 40–55, providing a structured assessment of the topical/aromatherapy use pattern that has been popular in Ayurvedic practice but lacks Western controlled-trial evidence
Future research directions for cognitive and longevity translation: The principal open question is whether the consistent preclinical Nrf2 and mitochondrial-biogenesis signal — well-summarized by the OHSU group’s preclinical work (e.g., Wright et al., 2022) and complementary in vitro literature — translates to durable cognitive or biological-aging endpoints in cognitively intact adults. Larger, longer-duration RCTs using standardized aqueous extract at the OHSU 2 g–4 g daily dose, with biological-age (epigenetic clock, p16-positive senescent cell burden) and functional cognitive endpoints, would substantially clarify the case for Centella asiatica as a longevity intervention. Equally important is a properly powered RCT addressing the hepatotoxicity question through systematic enzyme monitoring across thousands of participant-years of exposure
Future research directions for vascular and dermatologic translation: Larger independent (non-Belcaro-group) RCTs of Centella asiatica for atherosclerotic plaque progression — using modern carotid-IMT (Intima-Media Thickness, an ultrasound measure of vascular aging) and CT-angiographic plaque-stability endpoints — would resolve whether the Italian observational signal is robust. In dermatology, head-to-head RCTs against tretinoin in non-Asian populations, and longer-duration scar-prevention trials in surgical and burn populations, would complete the evidence base implied by the 2020 Kongkaew et al. network meta-analysis

Conclusion

Centella asiatica (Gotu Kola) is a millennia-old herbal remedy whose modern evidence base divides into well-supported, partially supported, and speculative domains. The strongest signal — moderate-certainty in the most rigorous synthesis — is symptomatic improvement of chronic venous insufficiency: reduced leg swelling, heaviness, and small-vessel dysfunction. Wound-healing benefit and topical skin-aging effects are also well documented, with smaller but reproducible effects on anxiety in patients with established generalized anxiety. Cognitive and longevity claims, prominent in traditional Ayurvedic framing and active preclinical research, are not yet supported by adequately powered human trials in cognitively healthy adults. The principal pharmacological actions — collagen synthesis, small-vessel-wall stabilization, and antioxidant-pathway activation — are mechanistically coherent and partly confirmed in humans through recent pharmacokinetic work.

Risk is dominated by a rare but documented idiosyncratic liver-injury signal alongside common, mild gastrointestinal and sedative effects. Sourcing matters: standardized pharmaceutical-grade extracts outperform raw-powder products in both effectiveness and traceability. The evidence base reflects active commercial sponsorship — particularly the vascular trials co-sponsored by Laboratoires Servier and run by the Belcaro and Cesarone research groups, who have direct financial interest in the standardized preparations under study — and benefits from independent academic work at the Oregon Health & Science University group and at Cochrane that helps anchor the synthesis. For an optimization-oriented audience, the case is most compelling for venous, skin, and stress-related applications under monitoring; weakest for cognitive enhancement in healthy adults; and genuinely open as a longevity intervention.

Top - Benefits - Risks - Protocol

Gotu Kola for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Reduction in Chronic Venous Insufficiency Symptoms

Improved Wound and Burn Healing

Low 🟩

Improvement in Facial Skin Aging and Wrinkles

Reduction in Anxiety and Stress Symptoms

Reduction in Diabetic Microangiopathy Symptoms

Speculative 🟨

Cognitive Enhancement in Healthy Aging ⚠️ Conflicted

Atherosclerotic Plaque Stabilization

Healthy-Lifespan Extension via Nrf2 and Mitochondrial Pathways

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Idiosyncratic Hepatotoxicity

Low 🟥

Gastrointestinal Discomfort

Headache and Drowsiness

Allergic Contact Dermatitis (Topical)

Speculative 🟨

Photosensitivity

Pregnancy and Lactation Risk

Mild Hyperglycemia ⚠️ Conflicted

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion